These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29522569)

  • 41. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
    Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma.
    He S; Gill BS; Heron DE; Kelley JL; Sukumvanich P; Olawaiye AB; Edwards RP; Comerci J; Beriwal S
    Pract Radiat Oncol; 2017; 7(1):19-25. PubMed ID: 27527897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
    Gul SK; Tepetam H; Yildiz F; Er I; Oksuz DC; Parvizi M; Ozden AS; Alicikus ZA; Sari SY; Alomari O; Gorken IB
    Clin Colorectal Cancer; 2023 Sep; 22(3):318-326. PubMed ID: 37336706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
    Ludmir EB; Kachnic LA; Czito BG
    Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
    Nilsson MP; Johnsson A; Scherman J
    Radiat Oncol; 2021 Aug; 16(1):152. PubMed ID: 34399812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
    de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
    Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
    Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
    J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
    Sher DJ; Thotakura V; Balboni TA; Norris CM; Haddad RI; Posner MR; Lorch J; Goguen LA; Annino DJ; Tishler RB
    Ann Oncol; 2012 Sep; 23(9):2391-2398. PubMed ID: 22425872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy.
    Yhim HY; Lee NR; Song EK; Kwak JY; Lee ST; Kim JH; Kim JS; Park HS; Chung IJ; Shim HJ; Hwang JE; Kim HR; Nam TK; Park MR; Shim H; Park HS; Kim HS; Yim CY
    Int J Cancer; 2011 Oct; 129(7):1752-60. PubMed ID: 21128253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy.
    Devisetty K; Mell LK; Salama JK; Schomas DA; Miller RC; Jani AB; Roeske JC; Aydogan B; Chmura SJ
    Radiother Oncol; 2009 Nov; 93(2):298-301. PubMed ID: 19717198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous Integrated Boost (SIB) Versus Sequential Boost in Anal Cancer Patients: A Single-Center Experience.
    Khosla D; Kapoor R; Dey T; Kataria V; Singh R; Kumar D; Oinam AS; Gupta R; Rana SS; Shah J; Singh H; Irrinki S; Madan R
    J Gastrointest Cancer; 2024 Jun; 55(2):759-767. PubMed ID: 38236375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
    Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
    Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
    Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
    Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
    DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
    Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy.
    Carpén T; Saarilahti K; Haglund C; Markkola A; Tarkkanen J; Hagström J; Mattila P; Mäkitie A
    Strahlenther Onkol; 2018 Aug; 194(8):759-770. PubMed ID: 29774396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
    Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
    J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Gilbert A; Drinkwater K; McParland L; Adams R; Glynne-Jones R; Harrison M; Hawkins MA; Sebag-Montefiore D; Gilbert DC; Muirhead R
    Eur J Cancer; 2020 Mar; 128():7-16. PubMed ID: 32109852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.